Skip to content
approvedSkin & Anti-Aging

Afamelanotide

Also known as: Scenesse, Melanotan-I, CUV1647, [Nle4, D-Phe7]-α-MSH

Afamelanotide is a synthetic tridecapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that selectively activates the melanocortin-1 receptor (MC1R) to stimulate eumelanin production. EMA-approved in 2014 and FDA-approved in 2019 as Scenesse, it is the first and only therapy for erythropoietic protoporphyria (EPP), a rare genetic photosensitivity disorder. The subcutaneous implant provides sustained photoprotection for approximately 60 days by increasing skin melanin content.

4 cited references·5 researched benefits

Quick Answer

Afamelanotide (Scenesse) is a synthetic α-MSH analog that stimulates melanin production via MC1R activation. It is the only FDA-approved treatment for erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe phototoxic reactions to visible light. Delivered as a subcutaneous implant every 60 days, it increases eumelanin levels to provide photoprotection, allowing EPP patients to tolerate sunlight exposure for the first time. It was originally developed as Melanotan-I.

Key Facts

Mechanism
Afamelanotide is a 13-amino-acid linear peptide based on α-MSH with two amino acid substitutions: Nle4 (norleucine replaces methionine at position 4) for oxidative stability, and D-Phe7 (D-phenylalanine replaces L-phenylalanine at position 7) for enhanced MC1R binding and metabolic resistance. Upon MC1R activation on melanocytes, it stimulates the cAMP/PKA/CREB pathway, upregulating tyrosinase and other melanogenic enzymes. This shifts melanin synthesis toward eumelanin (brown-black, photoprotective) over pheomelanin (red-yellow, photosensitizing). The resulting eumelanin absorbs UV and visible light, providing a biological sunscreen. In EPP, where protoporphyrin IX accumulation causes severe photosensitivity, increased eumelanin attenuates light penetration to deeper skin layers.
Research Status
approved
Half-Life
~30 minutes (peptide); implant releases over ~60 days
Molecular Formula
C₇₈H₁₁₁N₂₁O₁₉
Primary Use
Skin & Anti-Aging
Table of Contents

Benefits

  • Photoprotection in EPP — enables sunlight tolerance in patients who previously could not spend more than minutes outdoorsstrong
  • Increased sunlight exposure time — clinical trials showed a median increase of 60–70 hours of pain-free sun exposure over 6 monthsstrong
  • Quality of life improvement — patients report transformative improvements in daily activities, social participation, and psychological wellbeingstrong
  • Eumelanin-specific stimulation — promotes protective brown-black eumelanin rather than photosensitizing pheomelaninmoderate
  • Potential vitiligo repigmentation — early studies suggest MC1R activation may help restore pigmentation in vitiligo patchespreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous implant16 mgEvery 60 days (up to 5 implants per year)Biodegradable poly(D,L-lactide-co-glycolide) implant (1.7 cm × 1.45 mm) inserted via trocar into the suprailiac crest area. Administered by healthcare professionals only. Timing should precede anticipated sun exposure periods.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Skin darkening — expected pharmacological effect; generalized hyperpigmentation occurs in most patients and is reversible upon discontinuationcommon
  • Implant-site reactions — discoloration, pain, or nodule at the subcutaneous implant sitecommon
  • Nausea — reported in 15–20% of patients following implant insertioncommon
  • Headache and fatigue — mild symptoms reported in 10–15% of patientscommon
  • Darkening of pre-existing nevi (moles) — melanocytic nevi may darken; regular dermatological monitoring recommendedrare

Frequently Asked Questions

How does afamelanotide differ from Melanotan-II?
Afamelanotide (originally Melanotan-I) is a linear 13-amino-acid MC1R-selective peptide approved by the FDA/EMA with established safety data. Melanotan-II is a shorter cyclic 7-amino-acid peptide with non-selective melanocortin activity (MC1R-MC5R), causing unpredictable tanning, nausea, sexual arousal (MC4R), and cardiovascular effects. Melanotan-II has never been approved by any regulatory agency. Afamelanotide's MC1R selectivity makes it far safer but also means it only produces modest tanning versus Melanotan-II's dramatic darkening.
What is erythropoietic protoporphyria (EPP)?
EPP is a rare genetic disorder caused by mutations in the ferrochelatase gene, leading to accumulation of protoporphyrin IX in red blood cells, plasma, and skin. When exposed to visible light (especially 400–410 nm), protoporphyrin IX generates reactive oxygen species that cause severe burning pain, swelling, and scarring — even through window glass and clothing. Approximately 5,000–10,000 people are affected in the US. Before afamelanotide, the only management was strict light avoidance.
Can afamelanotide be used for general tanning?
Afamelanotide is exclusively indicated for EPP and is only available through a restricted REMS program. It produces modest tanning (eumelanin increase) over weeks — not the rapid dramatic tanning seen with unregulated Melanotan-II. Using a prescription orphan drug off-label for cosmetic tanning would be inappropriate medically, ethically, and legally. The implant formulation also makes casual use impractical.
Is long-term melanin stimulation safe regarding skin cancer risk?
Eumelanin (stimulated by afamelanotide) is photoprotective and associated with lower skin cancer risk, unlike pheomelanin which generates free radicals. Long-term follow-up studies of afamelanotide show no increased risk of melanoma or other skin cancers. However, patients undergo regular dermatological monitoring including full-body skin examinations and dermoscopy of nevi, as is prudent for any therapy that alters melanocyte activity. The EMA mandated a 15-year post-marketing safety surveillance program.
How quickly does afamelanotide work?
Melanin production increases gradually over 10–14 days after implant insertion, with peak photoprotection at 2–4 weeks. The effect lasts approximately 60 days as the implant slowly biodegrades and releases afamelanotide. Patients typically plan implant timing to coincide with seasons of greatest sun exposure (spring through fall). Full tanning develops over multiple implant cycles, with cumulative eumelanin deposition providing baseline photoprotection.

References

  1. 1
    Afamelanotide for erythropoietic protoporphyria: phase III randomized clinical trial(2015)PubMed ↗
  2. 2
    Long-term safety and efficacy of afamelanotide for erythropoietic protoporphyria(2019)PubMed ↗
  3. 3
    Melanocortin-1 receptor agonists for photoprotection: a systematic review(2017)PubMed ↗
  4. 4
    Clinical pharmacology of afamelanotide and its therapeutic potential(2013)PubMed ↗

Latest Research

Last updated: 2026-02-19